Long

SESN Price Target

On 8/17/2021 Canaccord Genuity brokerage Lower Price Target for SESN giving a Buy rating from $7.00 to $3.00.

Sesen Bio (SESN) flagship drug candidate Vicineum, failed to obtain FDA approval, but they will try a second time to get the regulatory go-ahead for the bladder cancer treatment.

buying long term calls could be a strategy for this one. volatility is likely after they announce the second FDA submission.
biotechbuycancerfdafdaapprovalFundamental AnalysisTechnical IndicatorssesensesenbioSESNTrend Analysisvicineum

Also on:

Disclaimer